Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Metolazone (SR-720-22), a thiazide-like diuretic, is mainly used to treat CHF-congestive heart failure and HBP-high blood pressure. Metolazone is marketed under the brand names Zytanix from Zydus Cadila, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.
ln Vitro |
Under the brand name Zytanix, Zydus Cadila, Zaroxolyn, and Mykrox distribute the thiazide diuretic metolazone (SR-720-22). It is mainly used to treat hypertension and congestive heart failure. Metolazone causes a decrease in blood volume and an increase in urine production by indirectly lowering the quantity of water that the kidneys reabsorb into the blood. As a result, blood pressure is lowered and excessive fluid accumulation in heart failure is avoided. Metolazone is occasionally used with highly effective loop diuretics like bumetanide or furosemide, however doing so might cause electrolyte imbalances and dehydration. The sodium-chloride symporter is inhibited by metolazone and other thiazide diuretics, which keeps water and salt from entering the renal tubular cells from the lumen. As a result, instead of being reabsorbed into the bloodstream, water stays in the lumen and is expelled as urine. When the filtrate reaches the distal convoluted tubule, the majority of the sodium in the lumen has already been reabsorbed, therefore thiazide diuretics have minimal effects on water balance and electrolyte levels. On the other hand, negative consequences like hypovolemia, hypotension, and low sodium levels might be linked to them.
|
---|---|
References |
[1]. Stern A. Metolazone, a diuretic agent. Am Heart J. 1976 Feb;91(2):262-3.
[2]. Thompson DM. A new antihypertensive: metolazone treatment of hypertension. J Kans Med Soc. 1977 Jul;78(7):337-9, 342. |
Molecular Formula |
C16H16CLN3O3S
|
---|---|
Molecular Weight |
365.83
|
CAS # |
17560-51-9
|
Related CAS # |
Metolazone-d7;2714484-71-4
|
SMILES |
O=S(C1=CC2=C(NC(C)N(C3=CC=CC=C3C)C2=O)C=C1Cl)(N)=O
|
InChi Key |
AQCHWTWZEMGIFD-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
|
Chemical Name |
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
|
Synonyms |
SR 720-22; SR-720-22; trade names: Zytanix, Zaroxolyn, Mykrox, Diulo, Oldren; SR720-22;
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (7.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7335 mL | 13.6676 mL | 27.3351 mL | |
5 mM | 0.5467 mL | 2.7335 mL | 5.4670 mL | |
10 mM | 0.2734 mL | 1.3668 mL | 2.7335 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.